Hypi, immunotherapy has had its ups and downs in the cancer therapeutic arena, and is currently the darling of the oncology avant garde, but meanwhile back in the clinic the same old principles of tried and treated treatments are still mostly employed. If a cancer is visible and accessible surgical extirpation will remain the treatment of choice in the foreseeable future. Nobody is going to treat a large cancer with immunotherapy alone. These agents, such as PPHM Bavituximab will be used to "prime" the target; immunologically "read" the target; stimulate the immune system to recognize the target; and then facilitate the body's manufacture of its own cancer killer antibodies to nullify growth or kill metastases and prevent recurrence. Likewise, external beam irradiation therapy will continue to be used into the foreseeable future because it is a killer of cancers (and normal cells), but it also promotes mutations. Cotara, a MAB carrying radioactive iodine, homes-in/docks on DNA-Histone, a component of dead/necrotic cells found in enormous concentrations in the center of cancers where rapidly multiplying cancer cells invariably outgrow their own blood supply and die. This miasma in the center of tumors hides some viable tumor cells which, when the "heat" is off, reconstitute and cause recurrences. Cotara kills from the inside out. Most cytotxics won't penetrate this area of tumor, including surface irradiation and chemo. In a perfect world an agent like ICT-107, about which you just posted, AND Cotara could be used in tandem and in synergy to provide even more survival time for sufferers of glioblastoma multiforme. Once approved for GBM Cotara can be used for other similar indications. No question but what anti-DNA histone is sensible. The question is will it be commercialized by PPHM, and in its present clunky form, or another.
